The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase IB/II study of neoadjuvant chemoradiotherapy with CRLX101 and capecitabine for locally advanced rectal cancer.
Michael Joseph Eblan
No relevant relationships to disclose
Hanna Kelly Sanoff
Consultant or Advisory Role - Amgen
Research Funding - Bayer; NCI; Novartis; PCORI
Autumn Jackson McRee
No relevant relationships to disclose
Bert H. O'Neil
No relevant relationships to disclose
Edward Graeme Garmey
Employment or Leadership Position - Cerulean Pharma
Stock Ownership - Cerulean Pharma
Meliessa G. Hennessy
Employment or Leadership Position - Cerulean Pharma
Stock Ownership - Cerulean Pharma
Scott Eliasof
Employment or Leadership Position - Cerulean Pharma
Stock Ownership - Cerulean Pharma
Joel E. Tepper
Research Funding - NIH/NCI
Andrew Wang
Employment or Leadership Position - Coordination Therapeutics
Research Funding - NIH/NCI